Navigation Links
ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Date:6/3/2008

SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFactor(R), for the treatment of advanced breast cancer at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL. CoFactor plus 5-FU (5-Fluorouracil) was determined to be a safe, well-tolerated and active treatment regimen in advanced breast cancer patients who are Herceptin receptor (Her2/neu) negative and who have failed prior taxane and anthracycline therapies. Data available from 31 patients indicated a 23% objective response rate with CoFactor plus 5-FU based on investigators' assessments. Objective response rate was based on the number of complete responses and partial responses observed in this study.

The poster presentation, entitled "5,10 methylenetetrahydrofolic acid with 5-fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase 2 study," was presented by Dr. Joachim P.H. Schupp, Vice President of Medical Affairs on June 2, 2008.

Historically, capecitabine (Xeloda(R)), a widely-used treatment for advanced breast cancer, has demonstrated response rates between 14% and 26% when studied as monotherapy in patients with advanced breast cancer who failed prior treatment with anthracyclines and taxanes. In this well-defined study population, two recently published, Phase 3 clinical trials, where capecitabine was the approved therapy, demonstrated response rates of 14% for capecitabine alone compared with 35% for capecitabine in combination with ixabepil
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... 2014  Eli Lilly and Company (NYSE: ... non-clinical study in genetically engineered mice examining combination ... antibody N3pG and beta-secretase inhibitor BACE (LY2811376). Data ... in removing clumps of amyloid-beta protein in the ... lead to Alzheimer,s disease (AD) – than use ...
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, ... company, today announced that the Food and Drug Administration ... provide comments on RCP,s Investigational New Drug ("IND") application ... trial in the US. Dr. Chris ... review and comments on our IND. When we receive ...
(Date:7/11/2014)... , July 11, 2014  Kindred Hospital ... to announce the opening of its new outpatient ... outpatient services to people with chronic, hard to ... which can lead to amputation, lower leg wounds ... have delayed closure, and traumatic injury wounds which ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2
... in Akron (ABIA) and the U.S. Food and Drug ... support and develop regulatory science for the safe and ... Effective today, the FDA and ABIA executed a Memorandum ... upon ABIA resources—including a library of test methods for ...
... Fero Industries, Inc. (OTCQB: FROI), announced today ... has completed the registration process to become a ... institutions within Mexico. This license, which is the ... Company to provide coverage to PEMEX (Petroleos Mexicanos), ...
Cached Medicine Technology:FDA, Austen BioInnovation Institute to Collaborate on the Safety and Performance of Materials used in Medical Devices 2FDA, Austen BioInnovation Institute to Collaborate on the Safety and Performance of Materials used in Medical Devices 3Fero Industries, Inc. Achieves First Certified Supplier Status to Distribute Sucanon® in Mexico 2Fero Industries, Inc. Achieves First Certified Supplier Status to Distribute Sucanon® in Mexico 3
(Date:7/13/2014)... July 14, 2014 MED-Ed Facilities is ... our next conference, April 7+8 in Boston at the ... at the recent event. Presentations by individuals or teams ... To review the types of sessions that were presented ... Submit your proposal today! , Conference Director, The ...
(Date:7/13/2014)... 2014 MillionaireCasket.com is a professional supplier of ... wood caskets are selling well in the global market. Recently, ... caskets and launched a special offer for all the ... all the company’s cherry caskets are made with superb materials. ... for people to show respect to the departed saint. MillionaireCasket.com ...
(Date:7/13/2014)... York (PRWEB) July 13, 2014 Intraocular ... Trends and Forecast 2013 - 2019 , Intraocular lens ... suffering from myopia or cataracts. The lenses are inserted ... the cataract surgery intraocular lens replaces the focusing power ... with original crystalline lens to deliver the light focusing ...
(Date:7/13/2014)... July 13, 2014 Victorian Hotel has ... promoting the rental of bikes for its "Cycle the ... Victorian Hotel to tour the area using a rental ... Bicycle enthusiasts love to call Vancouver home, as it ... cycle travel and picturesque journeys through the countryside. Vancouver ...
(Date:7/13/2014)... 13, 2014 Fuel additives are chemicals, ... diesel, jet fuel, kerosene, and so on, in order ... for reducing the corrosion effects caused by fuels and ... to any fuel, provide economies of scale in the ... the overall cost of the fuel products. , The ...
Breaking Medicine News(10 mins):Health News:MED-Ed Facilities Conference Call for Speakers Open 2Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4
... 18, 2011) Scientists at the Children,s Center for ... of Children,s Hospital Los Angeles today announced a breakthrough ... They have identified a protein called CD19-ligand (CD19-L) located ... facilitates the recognition and destruction of leukemia cells by ...
... 18 (HealthDay News) -- A disease the affects your legs ... About 9 million Americans over the age of 50 ... risk for heart attack, according to the Vascular Disease Foundation ... have the condition, the foundation says. PAD occurs when ...
... Center for World Health & Medicine at Saint Louis University ... forming a global research partnership that initially will focus on ... connected by a shared commitment to fight a devastating disease, ... scientists who formerly worked together in Chesterfield, Mo. GIBH ...
... Wittig, M.D., chief of the division of skin and ... Hackensack University Medical Center will present eleven different educational ... upcoming American Academy of Orthopaedic Surgeons Conference. Dr. Wittig ... practices in limb-sparing surgery. In 2009, he and his ...
... rich plasma (PRP) to promote healing in various surgeries, ... PRP did not improve healing after rotator cuff repair. ... investigators, will be presented at the upcoming American Orthopedic ... held Feb. 19 in San Diego, Calif., following the ...
... Parents and caregivers have traditionally relied on cribs, playpens ... The massive crib recalls followed by the announcement in ... Commission (CPSC) to ban drop-side cribs have caused many ... new study conducted by researchers at the Center for ...
Cached Medicine News:Health News:Scientists bioengineer a protein to fight leukemia 2Health News:Leg Discomfort Might Signal Heart Trouble 2Health News:Saint Louis U scientists partner on malaria research 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 2Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 3Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 4Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 5Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 6Health News:John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques 7Health News:Study shows PRP, commonly used technique to improve healing, doesn't work in rotator cuff surgery 2Health News:Study shows PRP, commonly used technique to improve healing, doesn't work in rotator cuff surgery 3Health News:New study finds 9,500 ED visits related to cribs, playpens and bassinets each year in US 2Health News:New study finds 9,500 ED visits related to cribs, playpens and bassinets each year in US 3
For Detection of Bile Component in Reflux Disease...
... With the advance of digital imaging ... advancing towards digital formats, allowing for ... This advance in digital pathology imaging ... occurred in radiology, and which is ...
... Analyzer II is a ... to enumerate fluorescently labeled ... selected and aligned. The ... CellTracks® Analyzer II, a ...
These Iron Control Slides make an excellent addition to your laboratory. Packed ten (10) control slides per box. Use SDL's Snap n' Stain for Iron Staining Kit alongside to save time an money mixing r...
Medicine Products: